netFormulary NHS
Lancashire and South Cumbria
Formulary
 Search
 Results

Looking for Tofacitinib found 12 matches
Open monograph to display formulary status BNF Category
  Tofacitinib Gastro-intestinal system - JAK inhibitors - 01.05.03
  Tofacitinib  (Xeljanz®) Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA: Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies (01.05.03)
link in drug section MHRA: Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies (10.01.03)
link in drug section MHRA: Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections (01.05.03)
link in drug section MHRA: Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections (10.01.03)
link in drug section MHRA: Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing (10.01.03)
link in drug section NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis (10.01.03)
link in drug section NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (10.01.03)
link in drug section NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis (01.05.03)
link in drug section NICE TA735: Tofacitinib for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA920: Tofacitinib for treating active ankylosing spondylitis (10.01.03)




Document Library Items Found

 
netFormulary